PRIMA: Closure of patent foramen ovale in patients with migraine with aura refractory

It is hypothesized that the presence of a right-left shunt can trigger migraine attacks. The aim of this study was to evaluate whether the closure of a patent foramen ovale may help treat patients with migraine with aura refractory to treatment. A total of 107 patients were included; 53 in the group of foramen ovale closure with Amplatzer PFO Occluder device and 41 in the medical treatment group. At one year there were no differences observed between the two groups in the number of migraine episodes although the group receiving device closure presented a more spaced frequency and lower intensity. 

3_david_smith
David Hildick-Smith
2014-09-17

Original title: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura

More articles by this author

EVERBIO II: Bio-absorbable stent Absorb versus everolimus-eluting or biolimus stents

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a...

EXCITE ISR: Excimer laser versus balloon angioplasty for stent restenosis of the superficial femoral

This multicenter, prospective, randomized trial compared the Excimer laser atherectomy (Excimer Laser Atherectomy = ELA, Spectranetics, Inc.) with a balloon angioplasty in patients with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...